The chitosan nanoparticle-based adjuvant CH-100 orchestrates multifaceted innate immune activation via STING-dependent and -independent pathways
International Immunology · 2026
DOI: 10.1093/intimm/dxaf054 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunology, 2026. Verfasst von Eri Nagai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Immunobiology, Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Techn…. Hauptthemen laut MEDLINE: Chitosan, Immunity, Innate, Adjuvants, Immunologic, Membrane Proteins. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, JSPS, KAKENHI.
Abstract (Originalsprache)
Adjuvants enhance vaccine efficacy by activating innate immunity; yet, the mechanisms of nanoparticle-based adjuvants remain incompletely defined. Here, we characterize CH-100, a chitosan nanoparticle adjuvant, and its capacity to coordinate dendritic cell (DC) activation and promote adaptive immune responses. CH-100 enhances antigen uptake, upregulates co-stimulatory molecules, and elicits antigen-specific antibody and cytotoxic T lymphocytes (CTL) responses. Mechanistically, CH-100 induces mitochondrial reactive oxygen species (ROS), leading to NLRP3 inflammasome activation, although NLRP3 is not essential for the observed adaptive responses. In parallel, CH-100 triggers the STING-IRF3 pathway to induce type I interferons; STING-deficiency partially diminishes antibody and CTL responses, suggesting involvement of additional signaling. Transcriptomic analysis reveals STING-independent upregulation of genes related to Th17 differentiation, accompanied by activation of TBK1, NF-κB, and p38 pathways in DCs, ultimately promoting Th17-skewed immunity. These findings demonstrate how CH-100 engages both STING-dependent and -independent innate pathways to shape adaptive immunity, offering mechanistic insights into chitosan-based adjuvants for future vaccine development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Immunobiology, Division of Biological Science, Graduate School of Science and Technology, Nara Institute of Science and Technology (NAIST), Ikoma 630-0192, Japan.
- Immune Dynamics in Viral Infections, National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Nagasaki 852-8523, Japan.
- Division of Vaccine Science, Department of Microbiology and Immunology, The University of Tokyo, Tokyo 108-8639, Japan.
- International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
- Life Science Collaboration Center (LiSCo), Nara Institute of Science and Technology (NAIST), Ikoma 630-0192, Japan.
- Medilux Research Center, Nara Institute of Science and Technology (NAIST), Ikoma 630-0192, Japan.
ORCID-Profile: Ken J Ishii
Förderung
- Japan Agency for Medical Research and Development
- JSPS
- KAKENHI
- Takeda Science Foundation
Zitieren
APA
Nagai, E., Ori, D., Kano, N., Ikegawa, M., Kobiyama, K., Ishii, K. J., Kawasaki, T., & Kawai, T. (2026). The chitosan nanoparticle-based adjuvant CH-100 orchestrates multifaceted innate immune activation via STING-dependent and -independent pathways. International Immunology. https://doi.org/10.1093/intimm/dxaf054
Vancouver
Nagai E, Ori D, Kano N, Ikegawa M, Kobiyama K, Ishii KJ, et al. The chitosan nanoparticle-based adjuvant CH-100 orchestrates multifaceted innate immune activation via STING-dependent and -independent pathways. International Immunology. 2026. doi:10.1093/intimm/dxaf054
BibTeX
@article{Nagai2026,
author = {Nagai, Eri and Ori, Daisuke and Kano, Norisuke and Ikegawa, Moe and Kobiyama, Kouji and Ishii, Ken J and Kawasaki, Takumi and Kawai, Taro},
title = {The chitosan nanoparticle-based adjuvant CH-100 orchestrates multifaceted innate immune activation via STING-dependent and -independent pathways},
journal = {International Immunology},
year = {2026},
doi = {10.1093/intimm/dxaf054}
}
EUVIMED